No abstract

Curcumin (Cur) has shown its potential in the treatment of a wide variety of ailments. As a result, several investigations on curcumin have been conducted in vitro, in vivo, and in clinical trials. Regrettably, researchers have largely lost interest in this excellent scaffold due to its chemical instability, poor solubility, and rapid metabolism, which directly affect its pharmacological properties. Alternatively, the researchers are working on it to improve the solubility and biological half-life, it is one of the most researched natural phytochemical to date. Among these, Dehydrozingerone (DZG), a curcumin half structure has garnered considerable research interest due to a wide spectrum of its biological activities. Thus, this study offers insight into the pharmacological activity of modified DZG conjugates (incorporate multiple effective modifications to the various positions), which have been developed since 2016. Additionally, the structure-activity relationship (SAR) of DZG hybrids was illustrated for their specific pharmacological properties. This review presents an update for the scientific community, which could assist in addressing the gaps, challenges and pharmacological aspects of DZG.

Direct transamidation is gaining prominence as a ground-breaking technique that generates a wide variety of amides without the requirement of acid–amine coupling or other intermediate steps.

In recent years, transamidation has been an essential topic in the formation of amide bonds over the conventional route due to chemoselectivity and greenside products. So many groups have disclosed new amide transformation techniques. Transamidation is typically classified into two categories based on amide activation: activated amide and unactivated amide. We conducted a review of the pertinent literature that discusses the cross amidation reactions of unactivated amides employing a variety of reagents, enabling contemporary research professionals to overcome synthetic barriers. Graphical abstract